ISB News

ISB Has Two New Patents

2014 is off to a great start for innovation in human health. ISB released two new patents in January that will make great contributions to personalized medicine. One of the patents, issued on January 27 and titled Use of Gene Expression Signatures to Determine Cancer Grade, has ISB President Dr. Lee Hood and ISB Senior Research Scientist Qiang Tian listed as inventors. Also sharing in that patent is Xiaowei Yan and the late Gregory Foltz. Read more about the patent here.

The second patent, released January 21, details New Biomarkers for Liver Injury. Sharing this patent are inventors Zhiyuan Hu; ISB Senior Research Engineer, Chris Lausted; and ISB President Dr. Lee Hood. Read more about this fascinating patent here.

And just as a reminder, if you do ever want to peruse all of ISB's US Patents with convenient links out to the US Government's official description of the patent, please visit https://www.isbscience.org/patents

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.